CoChat
Sign Up
Cited by 701vaccines and immunoinformatics approachesT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

STRUCTURE, FUNCTION, AND DIVERSITY OF CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES

Bjorkman, Pamela J., Parham, Peter·1990·Annual Review of Biochemistry
DOI 10.1146/annurev.bi.59.070190.001345
Open this paper in CoChat — free account

Abstract

Lymphocytes are the agents of antigenic specificity in the immune response. They divide into two groups: B cells that make immunoglobulins (Igs), and cells that perform a heterogenous set of functions including help for B cells, production of delayed-type hypersensitivity reactions, and the specific killing of virus-infected cells. Igs are the sole source of B cell specificity, whereas molecules from two diverse families of cell-surface glycoproteins, the T cell receptors (TcRs) and the major histocompatibility complex (MHC) glycoproteins, are the key elements of specificity in the T cell response to foreign antigens. \n \nTcRs, in common with the Ig receptors of B cells, are products of somatically rearranging genes and are clonally expressed (reviewed in Refs. 1, 2 and M. M. Davis, this volume). There are, however, two important differences in antigen recognition by these related groups of lymphocyte receptors. The first is a difference in the type of antigenic determinant (epitope) recognized: TcRs recognize short, linear, peptide determinants of 10-20 amino acids (3-5), the generation of which usually requires unfolding and proteolytic fragmentation ("processing") of the antigenic protein (6). By contrast, Igs commonly interact with epitopes formed by the three-dimensional structure of native proteins, although they can also be raised against peptides. The second difference in antigen recognition by Igs and TcRs is the involvement of a third molecule that performs the role of "presenting" the antigen to the receptor. For B cells such molecules do not exist; the antibody receptor forms a stable bimolecular complex with the antigenic protein. For T cells, the antigenic peptide must be bound by an MHC glycoprotein, and it is this complex of MHC molecule plus peptide that forms the structure rccognized by the TcR. MHC glycoproteins are thus peptide-binding proteins, and can be considered as antigen-presenting molecules. \n \nThere are two structurally distinct, but related, families of MHC molecules that present antigens to two subsets of T cells: Class I MHC molecules present antigens to T cells that express the CD8 cell-surface glycoprotein, and class II MHC molecules present antigens to T cells that express the CD4 cell-surface glycoprotein (7, 8). Other less rigid distinctions between class I and II MHC molecules are in the categories of antigen presented and in the functional activities of the responding T cells. Class I molecules commonly present peptides derived from endogenously synthesized proteins, such as viral components produced upon virus infection, and result in the stimulation of CD8-bearing cytotoxic (killer) T cells (9). On the other hand, class II molecules generally present peptides derived from exogenously synthesized proteins and stimulate CD4-bearing helper T cells (10). This specificity in the antigens presented by class I and class II molecules is thought to result from cellular segregation of the compartments or sites at which class I and class II MHC molecules encounter peptide (11, 12) (Figure 1). \n \nThat T cells have a dual requirement for recognition of both foreign antigen and a self-MHC molecule was first recognized by cellular immunologists in the early 1970s (13, 14): T cell recognition of antigen became known "MHC restricted," with considerable debate focussing upon its molecular interpretation and whether one or two receptor molecules were involved (15). Transfection experiments have now demonstrated that a single TcR recognizes both foreign antigen and MHC molecule (16). Discovery of the T cell requirement for fragmented protein antigens led to investigation of the antigen processing pathway, and revealed that incubation of antigen-presenting cells with short peptides circumvented the need for processing and provided the necessary target for the TcR (3, 17). Combining the concepts of MHC restriction and antigen processing led to the hypothesis that MHC molecules actually bind processed antigen fragments, thereby forming ligands for TcRs. The first direct evidence for this model came with the demonstration of binding of specific antigen peptides from hen egg lysozyme to a murine class II MHC molecule (18). \n \nThe experiments that defined and characterized MHC restriction were only possible because MHC genes are polymorphic, with the products of different alleles being distinguishable by both antibodies and TcRs. Indeed, alloreactive responses in which the immune system of one individual makes antibodies and T cells specific for the MHC molecules of another, are the basis for the immunological rejection of transplanted tissues that led to the discovery of the Major Histocompatibility Complex (19). The number of alleles at MHC loci and the complexity of their patterns of substitutions are unique when compared to other mammalian genes, and the basis for this diversity and its functional significance are long-standing questions (20). Analyses of MHC restriction (14), of T

Integrity signals

Registry

Crossref · 10.1146/annurev.bi.59.070190.001345

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Treatment of FRDA patients with 20 to 30 mg/kg of deferiprone efficiently decreased brain iron accumulation without apparent hematologic or neurologic adverse effects.

    “It was recently reported that treatment of FRDA patients with 20 to 30 mg/kg of deferiprone (3-hydroxy-1,2-dimethylpyridine-4-one), an iron chelator that is orally active, membrane permeable, blood–brain barrier crossing, and that transfers chelated iron to transferrin, efficiently decreased brain iron accumulation without apparent hematologic or neurologic adverse effects (25).”

    From Intracellular iron transport and storage: from molecular mechanisms to health implications (2008) · cites this paper as [25]

Cited by

Sorted by citations

Related

Authors
Bjorkman, P. J., & Parham, P.
Affiliations
California Institute of Technology (US)
ORCID
Parham, Peter
Venue
Annual Review of Biochemistry
Publisher
Annual Reviews
Published
1990-06
Volume
59
Issue
1
Pages
253-288
ISSN
  • 0066-4154 (ISSN-L)
  • 1545-4509
DOI
10.1146/annurev.bi.59.070190.001345
OpenAlex
W2153918116
Cited by
700
References
0
Citations by year
2026: 5 · 2025: 9 · 2024: 9 · 2023: 8 · 2022: 9 · 2021: 13 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 12 · 2016: 17 · 2015: 9 · 2014: 15 · 2013: 7 · 2012: 20
FWCI
15.83
Type
journal article
Language
en
Open access
closed
Locations
  • Annual Review of Biochemistry (publishedVersion)
  • PubMed (publishedVersion)
  • CaltechAUTHORS (California Institute of Technology) (submittedVersion)
Funders
U.S. Public Health Service
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
MHC class I, antigen presentation, peptide binding, CD8+ T cells, CD4+ T cells, T cell receptor, B cell receptor, MHC diversity, MHC polymorphism, MHC restriction, MHC class II, MHC class III, MHC class Ib
MeSH terms
Amino Acid Sequence, Antigenic Variation, Antigens, Antigens, Differentiation, T-Lymphocyte, Humans, Molecular Sequence Data, Peptides, Protein Conformation, Receptors, Antigen, T-Cell, T-Lymphocytes, Molecular Structure, Histocompatibility Antigens Class I, Antigens, CD, HLA-A2 Antigen, CD8 Antigens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review